Galapagos enters collaboration with AstraZeneca
The service division of integrated drug company Galapagos, BioFocus DPI, has established a drug discovery collaboration with AstraZeneca.
The service division of integrated drug company Galapagos, BioFocus DPI, has established a drug discovery collaboration with AstraZeneca.
BioFocus DPI will perform hit-to-lead medicinal chemistry services for AstraZeneca's respiratory and inflammatory drug discovery programs. The total con-tract value for Galapagos is Euro 650,000.
"We chose to work with BioFocus DPI because of their reputation and ability in modern lead generation methodologies. The ingenuity of their scientists will bring great value to the project," said Dr. Lars-Erik Arvidsson, vp of r&d at AstraZeneca, adding that "through this agreement we expect to deliver promising leads for candidate drugs."